On December 10th, Dr. Steve Shnyder, Senior Lecturer of Chemical Biology, School of Pharmacy and Medical Sciences (Faculty of Life Sciences), University of Bradford, UK, delivered a research seminar on the preclinical screening steps of new anti-cancer therapies. Dr. Shnyder started his presentation by showing the facilities available at the Institute of Cancer Therapeutics and how it’s been utilized in the screening process of anti-cancer drug discovery. In addition, he gave many examples novel anti-cancer compounds which have subsequently progressed to clinical trials and beyond, using both cell-based and in vivo plat forms.
Shnyder is an author on 65+ journal articles and numerous conference publications as well as three book chapters on in vivo methodology. In addition, he has significant experience in the areas of histopathology, biochemistry and cell biology. His research mainly focuses on the characterization of the reticuloplasmins as an anticancer drug targets, the pharmacology of vascular disrupting agents, the development of 3Rs methodologies, fluorescent assisted anti-cancer pharmacodynamic-pharmacokinetic modeling and evaluating tumor cell glycocalyx drugability.
The seminar was attended by MSc in Drug Discovery & Development (MDD) students as part of their research seminar course.
Dean of the College of Pharmacy, Prof. Khalifa commented: Our MDD students are privileged to be engaged in discussions with world class scientists during the graduate program. Such interactions will help position them for an exciting future as successful scientists.